Moffitt Presentations at AACR 2022

Time

Room

Type

Abstract No.

Abstract Title

Authors

12-1 p.m.

e-poster

5037

Distinct tumor-immune ecologies in NSCLC patients predict progression and define a clinical biomarker of therapy response

Sandhya Prabhakaran

12-1 p.m.

e-poster

5496

Efficacy and immune profiling of PI3K delta inhibitor zandelisib (ME-401) in a preclinical chronic lymphocytic leukemia (CLL) model

Kamira Maharaj

e-poster

5886

Pre-treatment adiposity measured by computed tomography and survival of women with high-grade serous ovarian cancer

Lauren C. Peres

12-1 p.m.

e-poster

5887

Association of ovarian tumor immune profiles with overall survival

Shelley S. Tworoger

12-1 p.m.

e-poster

6204

Age-related disparity in treatment outcome and adverse events among patients with metastatic colorectal cancer (mCRC)

Lingbin Meng

12-1 p.m.

e-poster

CT515

A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring KRAS or EGFR mutation

Andreas N. Saltos

12-1 p.m.

e-poster

CT529

A Phase 1b Study of CG0070 combined with nivolumab in cisplatin ineligible patients with muscle invasive bladder cancer

Roger Li

Time

Room

Type

Abstract No.

Abstract Title

Authors

208-210

Meet The Experts

Session ME25

Integrating evolutionary dynamics into treatment for metastatic cancers

Robert A. Gatenby

1:30-5 p.m.

Section 2

Poster

22 / 3

Sexual and gender minority patients report psychosocial concerns and low quality of life entering cancer treatment

Min-Jeong Yang,

1:30-5 p.m.

Section 13

Poster

277 / 18

High agreement between immune profiling assays on the detection of infiltrating immune cells in ovarian tumor tissue

Oscar E. Ospina

1:30-5 p.m.

Section 37

Poster

575 / 10

Ex vivo expansion of tumor infiltrating lymphocytes (TIL) from human renal cell carcinoma (RCC) tumors

Mohammed Alkhouli

3:20-3:35 p.m.

353-355

Oral

634

Mutation agnostic diagnosis of clonal hematopoiesis of indeterminate potential using fluctuating methylation clocks

Ryan O. Schenck

Time

Room

Type

Abstract No.

Abstract Title

Authors

353-355

Meet The Experts

Session ME02

Evolutionary Therapy

Alexander R. A. Anderson

9 a.m.-12:30 p.m.

Section 23

Poster

1101 / 14

CTNNB1 mutation can mediate resistance to EGFR, ALK and KRAS targeted therapies

Anurima Majumder

9 a.m.-12:30 p.m.

Section 30

Poster

1239 / 11

Prognostic and predictive value of PIK3CA mutations in metastatic CRC (mCRC)

Elaine Tan

9 a.m.-12:30 p.m.

Section 37

Poster

1354 / 13

Regulation and roles of polyamines in CD8+ T cell fate and function

Aya G. Elmarsafawi

9 a.m.-12:30 p.m.

Section 4

Poster

782 / 10

Multiomic single cell sequencing identified regulatory elements in prostate cells

Yijun Tian

9 a.m.-12:30 p.m.

Section 13

Poster

988 / 17

Epigenetic upregulation of neuropilin-1 promotes osteosarcoma progression and metastasis

Niveditha Nerlakanti

1:30-5 p.m.

Section 36

Poster

CT159 / 2

A phase 2a evolutionarily informed, mathematically guided adaptive abiraterone trial in metastatic castrate resistant prostate cancer

Jingsong Zhang

Time

Room

Type

Abstract No.

Abstract Title

Authors

9-12:30 a.m.

Section 3

Poster

2264 / 18

Co-infection with Epstein-Barr virus impacts oral HPV persistence

Brittney L. Dickey

9-12:30 a.m.

Section 3

Poster

2265 / 19

HCV seroprevalence and RNA detection rates across Florida, 2015-2018

Brittney L. Dickey

9-12:30 a.m.

Section 10

Poster

2448 / 20

Mmp-2 facilitates prostate cancer entry into and exit from dormancy

Mostafa Nasr

9-12:30 a.m.

Section 14

Poster

2522 / 15

Pathway and immune profile analysis of cyst-derived versus PanIN-derived pancreatic ductal adenocarcinomas

Margaret A. Park

9-12:30 a.m.

Section 15

Poster

2541 / 8

Immune cell clustering in ovarian cancer tumors and its association with survival

Alex C. Soupir

9-12:30 a.m.

Section 17

Poster

LB121 / 15

Multiplexed targeted proteomics of biomarkers for lung cancer treatment selection

Sudhir Putty Reddy

1:30-5 p.m.

Section 6

Poster

3014 / 2

PHGDH- A therapeutic vulnerability in melanoma

Neel N. Jasani

1:30-5 p.m.

Section 13

Poster

3193 / 20

Impact of stromal protection on in vivo response to ALK targeted therapies in NSCLC

Bina Desai

1:30-5 p.m.

Section 20

Poster

3218 / 5

Radiomic biomarkers to optimize treatment decision and predict patient outcomes in serous ovarian carcinoma

Jaileene Perez-Morales

1:30-5 p.m.

Section 31

Poster

3417 / 23

Effects of plasma exosome isolation methods on detectable multiomic profiles in cancer patients and healthy controls

Alex C. Soupir

1:30-5 p.m.

Section 39

Poster

3542 / 12

Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy

Hong Zheng

1:30-5 p.m.

La Nouvelle Orleans

Clinical Trials Mini Symposium

CT036

CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)

Roger Li

3:20-3:35 p.m.

New Orleans Theater C

Mini Symposium

3585

Disparities in cancer treatment delays or discontinuation among cancer patients diagnosed with SARS-CoV-2 infection: An analysis of the U.S. ASCO COVID-19 and cancer registry

Jessica Yasmine Islam

3:50-4:05 p.m.

295-296

Mini Symposium

3635

A randomized trial to examine the effectiveness of an LGBT cultural sensitivity training for oncologists: The COLORS trial

Matthew B. Schabath

Time

Room

Type

Abstract No.

Abstract Title

Authors

9 a.m.-12:30 p.m.

Section 3

Poster

3675 / 14

Epigenetic variations associated with therapy resistance among prostate tumors from Puerto Rican men

Jong Y. Park

9 a.m.-12:30 p.m.

Section 21

Poster

3911 / 7

Proteomic and transcriptomic subtypes of KRASG12C mutant lung cancer

Hitendra Singh Solanki